CervoMed (CRVO) Competitors

$2.87 -0.17 (-5.59%)

Closing price 03:59 PM Eastern

Extended Trading

$3.02 +0.15 (+5.05%)

As of 07:49 PM Eastern

CRVO vs. CNTB, EQ, DERM, RANI, and GNLX

Should you buy CervoMed stock or one of its competitors? MarketBeat compares CervoMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CervoMed include Connect Biopharma (CNTB), Equillium (EQ), Journey Medical (DERM), Rani Therapeutics (RANI), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.

How does CervoMed compare to Connect Biopharma?

CervoMed (NASDAQ:CRVO) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

In the previous week, Connect Biopharma had 3 more articles in the media than CervoMed. MarketBeat recorded 12 mentions for Connect Biopharma and 9 mentions for CervoMed. CervoMed's average media sentiment score of 0.65 beat Connect Biopharma's score of -0.57 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

CervoMed presently has a consensus target price of $22.60, suggesting a potential upside of 687.46%. Connect Biopharma has a consensus target price of $8.67, suggesting a potential upside of 295.74%. Given CervoMed's higher probable upside, analysts plainly believe CervoMed is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Connect Biopharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Connect Biopharma's return on equity of -122.29% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Connect Biopharma	N/A	-122.29%	-97.07%

CervoMed has a beta of -0.63, indicating that its share price is 163% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

CervoMed has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.63	-$26.97M	-$3.28	N/A
Connect Biopharma	$60K	2,298.04	-$55.48M	-$1.15	N/A

25.2% of CervoMed shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 35.4% of CervoMed shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Connect Biopharma beats CervoMed on 10 of the 16 factors compared between the two stocks.

How does CervoMed compare to Equillium?

CervoMed (NASDAQ:CRVO) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Equillium has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Equillium's return on equity of -61.43% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Equillium	N/A	-61.43%	-53.72%

Equillium has higher revenue and earnings than CervoMed. Equillium is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.63	-$26.97M	-$3.28	N/A
Equillium	$41.10M	2.72	-$22.40M	-$0.32	N/A

CervoMed presently has a consensus price target of $22.60, suggesting a potential upside of 687.46%. Equillium has a consensus price target of $7.67, suggesting a potential upside of 334.37%. Given CervoMed's higher probable upside, research analysts plainly believe CervoMed is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

25.2% of CervoMed shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CervoMed had 5 more articles in the media than Equillium. MarketBeat recorded 9 mentions for CervoMed and 4 mentions for Equillium. CervoMed's average media sentiment score of 0.65 beat Equillium's score of -0.75 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

CervoMed has a beta of -0.63, suggesting that its share price is 163% less volatile than the broader market. Comparatively, Equillium has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

Summary

Equillium beats CervoMed on 10 of the 16 factors compared between the two stocks.

How does CervoMed compare to Journey Medical?

CervoMed (NASDAQ:CRVO) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Journey Medical has a net margin of -14.82% compared to CervoMed's net margin of -672.80%. Journey Medical's return on equity of -35.57% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Journey Medical	-14.82%	-35.57%	-10.88%

CervoMed has a beta of -0.63, meaning that its share price is 163% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

25.2% of CervoMed shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 35.4% of CervoMed shares are held by company insiders. Comparatively, 15.0% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Journey Medical had 11 more articles in the media than CervoMed. MarketBeat recorded 20 mentions for Journey Medical and 9 mentions for CervoMed. CervoMed's average media sentiment score of 0.65 beat Journey Medical's score of -0.51 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Journey Medical	1 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Journey Medical has higher revenue and earnings than CervoMed. Journey Medical is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.63	-$26.97M	-$3.28	N/A
Journey Medical	$61.86M	2.72	-$11.43M	-$0.37	N/A

CervoMed currently has a consensus target price of $22.60, suggesting a potential upside of 687.46%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 111.38%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Journey Medical beats CervoMed on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to Rani Therapeutics?

CervoMed (NASDAQ:CRVO) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

25.2% of CervoMed shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rani Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Rani Therapeutics	N/A	-206.46%	-83.95%

CervoMed has a beta of -0.63, meaning that its stock price is 163% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

CervoMed currently has a consensus price target of $22.60, suggesting a potential upside of 687.46%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 889.37%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

CervoMed has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.63	-$26.97M	-$3.28	N/A
Rani Therapeutics	$1.63M	67.11	-$29.67M	-$0.41	N/A

In the previous week, CervoMed had 4 more articles in the media than Rani Therapeutics. MarketBeat recorded 9 mentions for CervoMed and 5 mentions for Rani Therapeutics. CervoMed's average media sentiment score of 0.65 beat Rani Therapeutics' score of 0.27 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

CervoMed beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to Genelux?

CervoMed (NASDAQ:CRVO) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

CervoMed presently has a consensus target price of $22.60, suggesting a potential upside of 687.46%. Genelux has a consensus target price of $18.00, suggesting a potential upside of 542.86%. Given CervoMed's stronger consensus rating and higher probable upside, equities analysts clearly believe CervoMed is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Genelux	N/A	-174.55%	-123.65%

25.2% of CervoMed shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 35.4% of CervoMed shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CervoMed has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.63	-$26.97M	-$3.28	N/A
Genelux	$10K	12,555.20	-$32.15M	-$0.85	N/A

CervoMed has a beta of -0.63, indicating that its share price is 163% less volatile than the broader market. Comparatively, Genelux has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

In the previous week, CervoMed had 6 more articles in the media than Genelux. MarketBeat recorded 9 mentions for CervoMed and 3 mentions for Genelux. CervoMed's average media sentiment score of 0.65 beat Genelux's score of -0.45 indicating that CervoMed is being referred to more favorably in the media.

Company	Overall Sentiment
CervoMed	Positive
Genelux	Neutral

Summary

CervoMed beats Genelux on 10 of the 15 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.15M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	N/A	18.70	20.58	25.09
Price / Sales	6.63	278.20	577.42	91.07
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.50	6.57	9.68	6.60
Net Income	-$26.97M	$24.30M	$3.55B	$335.71M
7 Day Performance	-23.87%	-3.56%	-2.07%	-2.03%
1 Month Performance	-27.89%	-7.86%	-3.90%	-1.90%
1 Year Performance	-67.35%	51.80%	29.39%	27.36%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	3.5789 of 5 stars	$2.87 -5.6%	$22.60 +687.5%	-65.4%	$28.15M	$4.01M	N/A	4	News Coverage Earnings Report Analyst Forecast Analyst Revision High Trading Volume
CNTB Connect Biopharma	2.9429 of 5 stars	$2.51 +7.1%	$8.67 +245.7%	+216.9%	$141.02M	$60K	N/A	110	Earnings Report Upcoming Earnings Analyst Downgrade
EQ Equillium	2.5114 of 5 stars	$2.19 -2.9%	$7.67 +250.9%	+392.0%	$138.22M	$41.10M	N/A	40	Earnings Report Analyst Downgrade
DERM Journey Medical	2.2607 of 5 stars	$4.95 -1.0%	$13.00 +162.6%	-9.8%	$135.48M	$61.86M	N/A	90	Earnings Report Analyst Revision
RANI Rani Therapeutics	2.9772 of 5 stars	$1.07 flat	$7.80 +629.0%	+51.8%	$132.35M	$1.63M	N/A	110	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. CNTB, EQ, DERM, RANI, and GNLX

How does CervoMed compare to Connect Biopharma?

Summary

How does CervoMed compare to Equillium?

Summary

How does CervoMed compare to Journey Medical?

Summary

How does CervoMed compare to Rani Therapeutics?

Summary

How does CervoMed compare to Genelux?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. CNTB, EQ, DERM, RANI, and GNLX

How does CervoMed compare to Connect Biopharma?

Does the media favor CRVO or CNTB?

Do analysts rate CRVO or CNTB?

Is CRVO or CNTB more profitable?

Which has more risk & volatility, CRVO or CNTB?

Which has better earnings & valuation, CRVO or CNTB?

Do institutionals and insiders believe in CRVO or CNTB?

Summary

How does CervoMed compare to Equillium?

Is CRVO or EQ more profitable?

Which has stronger valuation & earnings, CRVO or EQ?

Do analysts rate CRVO or EQ?

Do institutionals & insiders hold more shares of CRVO or EQ?

Does the media prefer CRVO or EQ?

Which has more volatility & risk, CRVO or EQ?

Summary

How does CervoMed compare to Journey Medical?

Is CRVO or DERM more profitable?

Which has more volatility and risk, CRVO or DERM?

Do institutionals and insiders hold more shares of CRVO or DERM?

Does the media prefer CRVO or DERM?

Which has better earnings and valuation, CRVO or DERM?

Do analysts recommend CRVO or DERM?

Summary

How does CervoMed compare to Rani Therapeutics?

Do institutionals & insiders hold more shares of CRVO or RANI?

Is CRVO or RANI more profitable?

Which has more risk and volatility, CRVO or RANI?

Do analysts prefer CRVO or RANI?

Which has higher valuation & earnings, CRVO or RANI?

Does the media refer more to CRVO or RANI?

Summary

How does CervoMed compare to Genelux?

Do analysts prefer CRVO or GNLX?

Is CRVO or GNLX more profitable?

Do insiders & institutionals hold more shares of CRVO or GNLX?

Which has preferable earnings and valuation, CRVO or GNLX?

Which has more risk & volatility, CRVO or GNLX?

Does the media prefer CRVO or GNLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools